Immunocore (IMCR)
(Delayed Data from NSDQ)
$32.99 USD
+0.22 (0.67%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $33.05 +0.06 (0.18%) 7:58 PM ET
1-Strong Buy of 5 1
F Value F Growth B Momentum F VGM
Fundamental Charts
About Return on Equity (TTM)
Immunocore Holdings PLC Sponsored ADR's return on equity, or ROE, is -5.86% compared to the ROE of the Medical - Biomedical and Genetics industry of -62.65%. While this shows that IMCR has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
IMCR 32.99 +0.22(0.67%)
Will IMCR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for IMCR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IMCR
CORT's Q2 Earnings Top Mark, Revenues Lag, '25 View Cut, Stock Down
FOLD Q2 Earnings Miss Mark, Revenues Beat on Higher Product Sales
IMCR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amarin's Q2 Earnings & Revenues Trump Estimates, Stock Rises
UTHR Q2 Earnings Miss Estimates, Higher Tyvaso Sales Aid Revenues Y/Y
Alkermes Q2 Earnings Beat Estimates, Proprietary Drugs Aid Sales
Other News for IMCR
Immunocore to report second quarter 2025 financial results and host call on August 7, 2025 | ...
Notable Two Hundred Day Moving Average Cross - IMCR
Tracking Baker Brothers Portfolio - Q1 2025 Update
Delcath Systems: Growing Fast, But Business Model Is Fragile
Immunocore Holdings (IMCR): HC Wainwright Maintains Buy Rating | IMCR Stock News